Mackenzie Financial Corp Cuts Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Mackenzie Financial Corp lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 4.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,455 shares of the biotechnology company’s stock after selling 198 shares during the quarter. Mackenzie Financial Corp’s holdings in Ascendis Pharma A/S were worth $561,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 31.9% during the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 193 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,462 shares of the biotechnology company’s stock worth $137,000 after buying an additional 714 shares during the period. Legato Capital Management LLC acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter worth $204,000. Gilbert & Cook Inc. purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $245,000. Finally, Sectoral Asset Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 51.7% during the 3rd quarter. Sectoral Asset Management Inc. now owns 4,241 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 1,445 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently weighed in on ASND. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Wedbush raised their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Morgan Stanley reissued an “equal weight” rating and set a $116.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, April 22nd. Finally, Citigroup increased their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

Ascendis Pharma A/S Stock Down 0.8 %

Shares of NASDAQ ASND opened at $135.90 on Friday. Ascendis Pharma A/S has a fifty-two week low of $66.03 and a fifty-two week high of $161.00. The business has a 50 day moving average price of $148.88 and a two-hundred day moving average price of $125.68. The firm has a market cap of $7.91 billion, a PE ratio of -14.69 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating the consensus estimate of ($2.15) by $0.49. The company had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, analysts anticipate that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.